Showing 3251-3260 of 5956 results for "".
- New Study Shows Eylea HD with Extended 12- or 16-Week Dosing Demonstrated Noninferior Vision Gains to Standard of Care Eyleahttps://modernod.com/news/lancet-study-eylea-hd-with-extended-12-or-16-week-dosing-demonstrated-noninferior-vision-gains-to-standard-of-care-eylea/2482151/Regeneron announced The Lancet published 1-year results from the pivotal PULSAR and
- Vital Tears Appoints Joseph Tauber, MD, as Chief Medical Officerhttps://modernod.com/news/vital-tears-appoints-joseph-tauber-md-as-chief-medical-officer/2482146/Vital Tears, a provider of autologous serum tears, has announced the appointment of Joseph Tauber, MD, as its Chief Medical Officer (CMO). In his new role, Dr. Tauber will lead Vital Tears’ research and development initiatives, provide physician education and training, and&nb
- Oculis Provides Updates on Late-Stage Clinical Trials; Announces Leadership Appointmentshttps://modernod.com/news/oculis-provides-updates-on-late-stage-clinical-trials-announces-leadership-appointments/2482135/Oculis provided updates its late-stage clinical trials, and also announced senior appointments to its management and advisory teams. The announcements were made during it R&D Day on Wednesday, February 28. “2024 promises to be another exciting year for Ocu
- WashU Awarded up to $20M to Create Portable Device to Scan for Eye Diseaseshttps://modernod.com/news/washu-awarded-up-to-20m-to-create-portable-device-to-scan-for-eye-diseases/2482115/Chao Zhou, a professor of biomedical engineering in the McKelvey School of Engineering at Washington University in St. Louis, has been working to improve optical coherence tomography (OCT) systems that can conduct high-resolution imaging of the eyes. Now, with an up to $20 million contract from t
- Ace Vision Group Names Val Kolesnitchenko, MD, as Chief Scientific Officerhttps://modernod.com/news/ace-vision-group-names-val-kolesnitchenko-md-as-chief-scientific-officer/2482095/Ace Vision Group announced that it has named Val Kolesnitchenko, MD, as Chief Scientific Officer. Dr. Kolesnitchenko has served in leadership roles for three decades in clinical ophthalmology practice and industry. Most recently, he held the position of Executive Director of Global
- Claris Bio Advances Corneal Healing Product Candidate; Secures New Fundinghttps://modernod.com/news/claris-bio-developer-of-corneal-healing-product-candidate-names-new-investor/2482042/Claris Bio unveiled the company and its lead program with a total of $57 million invested. Claris, initially funded in 2020, is developing recombinant human variant hepatocyte growth factor, dHGF, to accelerate and improve the quality of corneal healing in patients with corneal eye dise
- UAlbany Scientists Explore New Molecular Tool to Treat Retinal Degenerative Diseasehttps://modernod.com/news/ualbany-scientists-explore-new-molecular-tool-to-treat-retinal-degenerative-disease/2482011/University at Albany scientists at the College of Arts and Sciences’ RNA Institute, in collaboration with a research team from the University of Buffalo’s Jacobs School of Medicine and Biomedical Sciences, have received a 4-year, $1.8 million grant from the National Eye
- Ophtec Launches Precizon Go IOL for Enhanced Intermediate Visionhttps://modernod.com/news/ophtec-launches-precizon-go-iol-for-enhanced-intermediate-vision/2482002/Ophtec announced the launch of the Precizon Go, a hybrid acrylic IOL designed to provide distance and enhanced intermediate vision. The lens is designed to offer natural vision at far and enhanced intermediate vision, without compromising the quality of vision at any
- EyePoint Pharmaceuticals Announces Positive Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 in Wet AMDhttps://modernod.com/news/eyepoint-pharmaceuticals-announces-positive-topline-data-from-the-phase-2-davio-2-trial-of-eyp-1901-in-wet-amd/2481990/In a phase 2 study, EyePoint Pharmaceuticals’ wet AMD drug candidate demonstrated noninferiority to Eylea—with a less frequent dosing regimen. EyePoint leadership said the sustained-release implant could represent a 'paradigm-altering maintenance treatment' for patients with w
- Alcon Canada Launches Clareon Vivity, its Latest Advancement in Presbyopia Correcting IOLshttps://modernod.com/news/alcon-canada-launches-clareon-vivity-its-latest-advancement-in-presbyopia-correcting-iols/2481956/Alcon announced that Clareon Vivity, the first and only non-diffractive extended depth of focus (EDOF) IOL on Alcon’s lens platform, is now available in Canada. [1-6] Clareon Vivity is designed to provide high-quality vision from distance to functional near with a visual dist